JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $8,830,000 | +1.2% | 193,183 | -0.7% | 0.01% | 0.0% |
| Q3 2017 | $8,726,000 | +54.9% | 194,508 | +3.2% | 0.01% | +50.0% |
| Q2 2017 | $5,634,000 | +46.8% | 188,481 | +9.0% | 0.00% | +33.3% |
| Q1 2017 | $3,839,000 | +12.7% | 172,990 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $3,405,000 | -39.2% | 180,632 | -3.2% | 0.00% | -25.0% |
| Q3 2016 | $5,599,000 | -54.9% | 186,586 | -42.2% | 0.00% | -60.0% |
| Q2 2016 | $12,419,000 | +85.4% | 323,062 | +83.7% | 0.01% | +100.0% |
| Q1 2016 | $6,699,000 | -9.6% | 175,882 | +4.4% | 0.01% | -16.7% |
| Q4 2015 | $7,410,000 | +146.1% | 168,525 | +127.7% | 0.01% | +200.0% |
| Q3 2015 | $3,011,000 | -3.6% | 74,007 | +26.3% | 0.00% | 0.0% |
| Q2 2015 | $3,124,000 | +503.1% | 58,575 | +585.4% | 0.00% | – |
| Q1 2015 | $518,000 | -60.8% | 8,546 | -66.3% | 0.00% | -100.0% |
| Q4 2014 | $1,323,000 | – | 25,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |